BPH Corporate

Shares / Stock Code


Stock Exchange / Sharemarket


BPH is a biotechnology company specialising in the development of cancer treatments. The company is developing products to detect and treat breast, colorectal and prostate cancer through its project with the University of Western Australia and the world-class research team at the Laboratory for Cancer Medicine at the Western Australian Institute for Medical Research (WAIMR). The company was listed on the ASX in August 2004. BPH is working to commercialise a portfolio of Australian biomedical research discovered by Australian universities, medical institutes and hospitals, targeting large global markets. Its head office is situated in East Perth.

The company is working on commercialising cancer research, HLS5, developed by Professor Peter Klinken and his team at the internationally recognised WAIMR. HLS5 is a candidate tumour suppressor gene (a gene that allows cancer cells to grow uncontrolled when switched off or mutated). Genetic testing for cancer with diagnostic tests using genes such as HLS5 may lead to cancer being found at an earlier or treatable stage. Major customers of BPH include universities, medical institutes and hospitals such as the Royal Perth Hospital, Sir Charles Gairdner Hospital, Fremantle Hospital and the University of Western Australia. Competitors are mainly other R&D companies specialising in cures for cancer, such as Cytopia Limited (CYT).

BPH Corporate Products and Services

  • Biomedical commercialization

BPH Corporate Locations and Subsidiaries

BPH Corporate Head Office
14 View Street,
WA 6006

Phone: (08) 9328 8366
Fax: (08) 9328 8733

BPH Corporate Share Price

Submitted by ASX Listed Company on 2 March, 2010 - 07:09